Medical Condition News

RSS

Revlimid now available to multiple myeloma patients in Nova Scotia

Following the broadcast on CTV's W5 of the plight of multiple myeloma patient Frank Boyd and his inability to obtain appropriate drug treatment, on March 27, the President of Myeloma Canada, John Lemieux, immediately wrote to the Honourable Maureen MacDonald, Minister of Health of Nova Scotia urging her to implement an interim arrangement to ensure that Revlimid is available to multiple myeloma patients, including Mr. Boyd, in Nova Scotia.

16 Apr 2010

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

CombinatoRx, Incorporated today announced that preclinical data on its discovery of novel synergistic drug combinations for the treatment of cancer will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

16 Apr 2010

Sexual minorities more likely to experience posttraumatic stress disorder

A new study from researchers at the Harvard School of Public Health (HSPH) and Children's Hospital Boston has found that gay men, lesbians, bisexuals, and heterosexuals who have ever had a same-sex sex partner are one-and-a-half to two times as likely to experience violent events, especially in childhood, than the general population.

16 Apr 2010

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Affymax, Inc. and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease. The data provide hypotheses for further investigation of this agent in anemia management in this patient population.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

Illinois' tobacco tax would bring in $297.6M in new revenue, reduce youth smoking

A new poll released today finds that 74 percent of Illinois voters support raising the tobacco tax by $1 per pack to cut the state's budget deficit and reduce youth tobacco use.

16 Apr 2010

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

Celsion Corporation today announced that Dr. Ronnie T.P. Poon, a principal investigator of the Phase I ThermoDox® dose escalation trial, held a press conference at the University of Hong Kong to provide an update on the long-term follow-up data from patients treated at his center as well as present illustrative patient case studies. The Phase I trial was conducted in 2006.

16 Apr 2010

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

The University Hospital of Zurich has become the first medical center in the world to commence treating cancer patients with the revolutionary TrueBeam system from Varian Medical Systems, a new platform for image-guided radiotherapy and radiosurgery that was designed from the ground up to treat a moving target with unprecedented speed and precision.

16 Apr 2010

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, has initiated a long-term (26-week) toxicology study of CEQ508 – the company's lead drug candidate based on its proprietary tkRNAi technology. This study is designed to enable a Phase II clinical trial slated for 2011. CEQ508 targets beta-catenin, a key oncogene implicated in the formation of colonic polyps and in the progression of polyps to colorectal cancer.

16 Apr 2010

Self-monitoring of Coumadin levels reduces risk of blood clots by 50%: Study

A new review of existing research finds that many patients who take an anti-clotting drug or "blood-thinner" can benefit from monitoring the levels of the drug themselves instead of going to clinics for blood tests.

16 Apr 2010

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.

16 Apr 2010

FDA grants marketing clearance for Cambridge Heart's MTWA OEM module

Cambridge Heart, Inc., today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc..

16 Apr 2010

Long-term monitoring and education needed to protect lungs of young patients

St. Jude Children's Research Hospital investigators have identified childhood cancer survivors who are at increased risk for deteriorating lung health, in part due to the lifesaving bone marrow transplants they underwent years earlier.

16 Apr 2010

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

New research investigating neurological decline in a population of "super healthy" elderly subjects found that the decline in neurological function of the peripheral nervous system attributed to aging may be related to metabolic factors, such as blood sugar levels, even if these factors are within the normal range.

16 Apr 2010

UALR researcher receives federal grant to track estrogen-mimicking compounds in consumer products

Dr. Jerry Darsey, professor of chemistry in UALR's College of Science and Mathematics, has received $77,000 from a federal Food and Drug Administration grant to develop methods to track estrogen mimicking compounds in various products and assess how use of the products affect women.

16 Apr 2010

LOTS results of Myozyme in older children and adults with Pompe disease published

Genzyme Corp. today announced that the results from its Late-Onset Treatment Study have been published in today's New England Journal of Medicine. The study was undertaken to evaluate the safety and efficacy of Myozyme (alglucosidase alfa) in older children and adults with Pompe disease.

16 Apr 2010

IBA's PBS system for Proton Therapy granted CE Mark

IBA's second generation Pencil Beam Scanning system for Proton Therapy, which further enhances the performance of anti-cancer proton treatments, has been granted the CE Mark, certifying that the product has met European Union medical device regulations.

16 Apr 2010

Moving is the best medicine for arthritic pain

The burden of arthritis is greater for African Americans and Hispanics, despite lower prevalence among these groups according to a Centers for Disease Control and Prevention (CDC) report published in the May issue of Preventing Chronic Disease.

16 Apr 2010

New scale more suitable for predicting depressive symptoms

A research team has tested the utility of the short version of WHO-DAS II, a tool to assess within five minutes disability in patients with depression, "which in the case of primary care is even more practicable than the long version of the instrument." In Spain, more than 10% of the population suffer from severe depression.

16 Apr 2010

Certain genetic variations linked to tooth decay, periodontitis

Certain genetic variations may be linked to higher rates of tooth decay and aggressive periodontitis, according to two recently published papers by researchers at the University of Pittsburgh School of Dental Medicine and their collaborators.

16 Apr 2010

Medical Condition News

Revlimid now available to multiple myeloma patients in Nova Scotia

CombinatoRx's synergistic drug combinations for cancer treatment to be highlighted at AACR 2010

Sexual minorities more likely to experience posttraumatic stress disorder

Data from Phase 2 clinical trials of Hematide/peginesatide presented at NKF Annual Meeting

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Illinois' tobacco tax would bring in $297.6M in new revenue, reduce youth smoking

Celsion announces presentation of long-term follow-up data from Phase I ThermoDox dose escalation trial

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

Cequent Pharmaceuticals commences toxicology study of CEQ508 tkRNAi-based therapeutic candidate

Self-monitoring of Coumadin levels reduces risk of blood clots by 50%: Study

Rexahn Pharmaceuticals to present RX-8243 anticancer compound data at 101st AACR Annual Meeting

FDA grants marketing clearance for Cambridge Heart's MTWA OEM module

Long-term monitoring and education needed to protect lungs of young patients

Age-related declines in peripheral nerve function may be related to metabolic factors: Study

UALR researcher receives federal grant to track estrogen-mimicking compounds in consumer products

LOTS results of Myozyme in older children and adults with Pompe disease published

IBA's PBS system for Proton Therapy granted CE Mark

Moving is the best medicine for arthritic pain

New scale more suitable for predicting depressive symptoms

Certain genetic variations linked to tooth decay, periodontitis

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News